A Rapid Appraisal of Factors Influencing Praziquantel Treatment Compliance in Two Communities Endemic for Schistosomiasis in Côte d’Ivoire

Coulibaly, Jean T.; Ouattara, Mamadou; Barda, Beatrice; Utzinger, Jürg; N’Goran, Eliézer K.; Keiser, Jennifer

doi:10.3390/tropicalmed3020069

Cited by 21 publications

(33 citation statements)

References 40 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the study nding in Ivory Coast, overall PZQ treatment coverage rate was 47.6% (2730/5733). It also revealed that treatment compliance (acceptance and swallowing) status of PZQ was signi cantly higher in males than females (X 2 = 19.96, p < 0.001) (24) (24). This nding is consistent with the present study nding, the odds of acceptance and swallowing of PZQ is 27% more likely for males compared with their counter parts.…”

Section: Discussionsupporting

confidence: 85%

Praziquantel treatment coverage among school age children against Schistosomiasis and associated factors in Ethiopia: a cross-sectional survey, 2019

Chisha

Zerdo

Asnakew

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: World Health Organization estimated that 779 million people are at risk of getting schistosomiasis (SCH) and 240 million people were infected worldwide. SCH due to schistosoma mansoni (S. mansoni) is a wide public health problem in Ethiopia. The aim of the survey was to quantify national and district disaggregated treatment coverage status for SCH and compare validated coverage with the one reported. Methods: Community based cross-sectional survey was conducted in April 2019 among households with school age children (SAC) 5-14 years in seven purposively selected districts of the country. Segments to be surveyed were randomly selected and households to be interviewed from each segment were determined using systematic sampling technique. A total of 3,378 households visited and 5,679 SAC (5-14 years) were interviewed.Results: Overall reported treatment coverage of PZQ against SCH was 4286 (75.5%). Males were 27% more likely to swallow the drug (AOR= 1.27; 95% CI: 1.09, 1.47) than females. SAC with age 10-14 years were 45% more likely to swallow the drug compared with their counter parts (5-9 years), (AOR =1.45; 95% CI: 1.25, 1.69). Statistically significant association was observed between PZQ swallowing with school enrollment and heard about mass drug administration. Swallowing status of PZQ against SCH significantly higher for SAC treated in districts applied integrated treatment approach (87.5%) compared with SAC treated in vertical treatment approach (72.5%). SACs were asked for reasons for not taking the drug and the main reported reason for not swallowing PZQ in the present study was none attending of the school.Conclusion and recommendation : Over all treatment coverage of PZQ against SCH in the present study was 75.5%. Although it is in accordance with WHO recommendation for Ethiopia, national programmatic improvements are necessary to achieve higher coverage in the future. To increase treatment coverage for PZQ against SCH in Ethiopia, school based training should target all schools. Moreover, mobilization, sensitization and implementation of the community wide treatment need to be improved.

show abstract

Section: Discussionsupporting

confidence: 85%

Praziquantel treatment coverage among school age children against Schistosomiasis and associated factors in Ethiopia: a cross-sectional survey, 2019

Chisha

Zerdo

Asnakew

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The difficulty in developing good coverage estimates has been well-documented. [5][6][7]28 In planning the SCORE studies, annual coverage surveys were considered, but ultimately were not required by the harmonized study protocol because of lack of consensus on how to conduct coverage surveys and concerns about the financial and human resources that would be required. Instead, it was deemed acceptable to collect data on the numbers treated and compare those with the population eligible for treatment.…”

Section: Discussionmentioning

confidence: 99%

“…4 Problems with both measuring MDA coverage and achieving targets have been reported previously. [5][6][7] The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) was launched in 2008 with funding from the Bill & Melinda Gates Foundation to contribute to the evidence base for programmatic decision-making related to schistosomiasis control and elimination. The SCORE research portfolio includes studies related to topics such as control and elimination of schistosomiasis, diagnostic test development and validation in real-world settings, and changes in schistosome population genetics in response to drug pressure.…”

Section: Introductionmentioning

confidence: 99%

Lessons Learned in Conducting Mass Drug Administration for Schistosomiasis Control and Measuring Coverage in an Operational Research Setting

Binder

Campbell

Castleman

et al. 2020

The American Journal of Tropical Medicine and Hygiene

Self Cite

View full text Add to dashboard Cite

The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) was created to conduct research that could inform programmatic decision-making related to schistosomiasis. SCORE included several large cluster randomized field studies involving mass drug administration (MDA) with praziquantel. The largest of these were studies of gaining or sustaining control of schistosomiasis, which were conducted in five African countries. To enhance relevance for routine practice, the MDA in these studies was coordinated by or closely aligned with national neglected tropical disease (NTD) control programs. The study protocol set minimum targets of at least 90% for coverage among children enrolled in schools and 75% for all school-age children. Over the 4 years of intervention, an estimated 3.5 million treatments were administered to study communities. By year 4, the median village coverage was at or above targets in all studies except that in Mozambique. However, there was often a wide variation behind these summary statistics, and all studies had several villages with very low or high coverage. In studies where coverage was estimated by comparing the number of people treated with the number eligible for treatment, denominator estimation was often problematic. The SCORE experiences in conducting these studies provide lessons for future efforts that attempt to implement strong research designs in real-world contexts. They also have potential applicability to country MDA campaigns against schistosomiasis and other NTDs, most of which are conducted with less logistical and financial support than was available for the SCORE study efforts.

show abstract

“…According to the study finding in Ivory Coast, overall PZQ treatment coverage rate was 47.6% (2730/5733). It also revealed that treatment compliance (acceptance and swallowing) status of PZQ was significantly higher in males than females (X 2 = 19.96, p < 0.001) [ 24 ]. This finding is consistent with the present study finding, the odds of acceptance and swallowing of PZQ is 27% more likely for males compared with their counter parts.. A study finding in Uganda revealed that over all PZQ treatment coverage was 48.8%.…”

Section: Discussionmentioning

confidence: 99%

Praziquantel treatment coverage among school age children against Schistosomiasis and associated factors in Ethiopia: a cross-sectional survey, 2019

et al. 2020

View full text Add to dashboard Cite

Background World Health Organization estimated that 779 million people are at risk of getting schistosomiasis (SCH) and 240 million people were infected worldwide. SCH due to Schistosoma mansoni (S. mansoni) is a wide public health problem in Ethiopia. The aim of the survey was to quantify national and district disaggregated treatment coverage status for SCH and compare validated coverage with the one reported. Methods Community based cross-sectional survey was conducted in April 2019 among households with school age children (SAC) 5–14 years in seven purposively selected districts of the country. Segments to be surveyed were randomly selected and households to be interviewed from each segment were determined using systematic sampling technique. A total of 3378 households visited and 5679 SAC (5–14 years) were interviewed. Results Overall reported treatment coverage of Praziquantel (PZQ) against SCH was 4286 (75.5%). Males were 27% more likely to swallow the drug (AOR = 1.27; 95% CI: 1.09, 1.47) than females. SAC with age 10–14 years were 45% more likely to swallow the drug compared with their counter parts (5–9 years), (AOR =1.45; 95% CI: 1.25, 1.69). There is statistically significant association between PZQ swallowing status with school enrollment. (AOR = 20.90, 95% CI: 17.41, 25.08). Swallowing status of PZQ against SCH significantly higher for SAC treated in districts applied integrated treatment approach (87.5%) compared with SAC treated in vertical treatment approach (72.5%); P-value < 0.001. SACs were asked for reasons for not taking the drug and the main reported reason for not swallowing PZQ in the present study was none attending of the school. Conclusions Over all treatment coverage of PZQ against SCH in the present study was 75.5%. Although it is in accordance with WHO recommendation for Ethiopia, national programmatic improvements are necessary to achieve higher coverage in the future. To increase treatment coverage for PZQ against SCH in Ethiopia, school based training should target all schools. Moreover, mobilization, sensitization and implementation of the community wide treatment need to be improved.

show abstract

A Rapid Appraisal of Factors Influencing Praziquantel Treatment Compliance in Two Communities Endemic for Schistosomiasis in Côte d’Ivoire

Cited by 21 publications

References 40 publications

Praziquantel treatment coverage among school age children against Schistosomiasis and associated factors in Ethiopia: a cross-sectional survey, 2019

Praziquantel treatment coverage among school age children against Schistosomiasis and associated factors in Ethiopia: a cross-sectional survey, 2019

Lessons Learned in Conducting Mass Drug Administration for Schistosomiasis Control and Measuring Coverage in an Operational Research Setting

Praziquantel treatment coverage among school age children against Schistosomiasis and associated factors in Ethiopia: a cross-sectional survey, 2019

Contact Info

Product

Resources

About